Business Context and Reporting Period
This Form 8-K, filed on August 13, 2025, reports the completion of a transformative merger and related corporate actions by Vyome Holdings, Inc. (formerly ReShape Lifesciences Inc.). The reporting period focuses on events consummated on August 15, 2025, including the merger with Vyome Therapeutics, Inc., a reverse stock split, and significant changes to the Board of Directors and executive leadership.
Key Financial Metrics and Transactions
- Asset Sale Proceeds: The Company sold its assets (excluding cash) to Ninjour Health International Limited (an affiliate of Biorad Medisys) for an agreed purchase price of $2.25 million in cash, subject to working capital adjustments.
- Equity Financing: Immediately following the merger, the Company sold 529,137 shares of Common Stock at $11.02 per share. Additionally, Vyome Limited sold 999 shares at $937.14 per share, subject to put-call option agreements.
- Executive Compensation: The Interim Chief Financial Officer, Robert Dickey, was appointed to a one-year term with compensation of $15,000 per calendar month.
- Capital Structure: A 1-for-4 reverse stock split was effected to maintain Nasdaq listing compliance. The Company's name was changed to Vyome Holdings, Inc., and the trading symbol remains "HIND" on The Nasdaq Capital Market.
Material Changes Versus Prior Period
- Corporate Identity: The registrant changed its name from ReShape Lifesciences Inc. to Vyome Holdings, Inc. effective August 15, 2025.
- Leadership Overhaul: The entire prior Board of Directors and executive team (including CEO Paul Hickey and CFO Tom Stankovich) resigned. A new six-member Board was elected, and Venkateswarlu Nelabhotla was appointed CEO.
- Asset Disposition: The Company divested its legacy assets to Biorad, effectively exiting its previous business operations in favor of the merged entity's focus.
- Shareholder Base: Existing Vyome shareholders received ReShape common stock based on a predetermined ratio, while certain Indian shareholders are subject to put-call option agreements.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue forecasts, or profit outlooks for the combined entity. Management commentary is limited to the successful closing of the Merger and the Asset Sale.
Risks and Contingencies:
- Regulatory Compliance: The reverse stock split was necessitated to meet Nasdaq minimum bid price requirements.
- Contractual Limitations: The filing includes a disclaimer that representations and warranties in the Merger Agreement were made solely for the transaction and may not reflect factual information or materiality standards for stockholders.
- Future Agreements: The Company intends to enter into a formal employment agreement with the new CEO, details of which will be disclosed in a subsequent report.
Investor Verification Checklist
- Verify the final exchange ratio used to convert Vyome shares into Vyome Holdings common stock.
- Confirm the final cash consideration received from the Biorad asset sale after working capital adjustments.
- Review the terms of the put-call option agreements affecting Indian shareholders of Vyome Limited.
- Monitor the upcoming filing for the formal employment agreement and compensation package for CEO Venkateswarlu Nelabhotla.
- Check the Company's next periodic report (10-Q or 10-K) for the consolidated financial position post-merger.